# Triple Negative Breast Cancer and Celecoxib. Pilot Study

Source: https://onco.cc/trials/nct07104266/  
OnCo record `nct07104266` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of celecoxib in triple-negative breast cancer, run by Université de Sherbrooke, now recruiting.

## Summary

Triple Negative Breast Cancer and Celecoxib. Pilot Study is a phase 2, randomised interventional study registered as NCT07104266 by Université de Sherbrooke, with a registry enrolment figure of 30 participants, started 2025-08-04 and due to reach its primary completion in 2028-08-04. Interventions recorded: Celecoxib (Celebrex); Placebo. Conditions listed: Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* TNBC status confirmed by pathology". Sites: Canada. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07104266
- Phase: 2
- Setting: Determine Whether Administering Celecoxib During Radiotherapy Can Reduce the Risk of Recurrence of Triple-negative Breast Cancer. Pilot Study
- Sponsor: Université de Sherbrooke
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07104266: https://clinicaltrials.gov/study/NCT07104266

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- drugs: [Celecoxib](https://onco.cc/drugs/celecoxib/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07104266.json